Publications

Virchows Archiv : an international journal of pathology

An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.

01-09-2016

Breast cancer research : BCR

Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.

05-08-2016

Investigative radiology

Prediction Model For Extensive Ductal Carcinoma In Situ Around Early-Stage Invasive Breast Cancer.

01-07-2016

Oncotarget

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.

07-06-2016

AJR. American journal of roentgenology

Evaluation of a Hanging-Breast PET System for Primary Tumor Visualization in Patients With Stage I-III Breast Cancer: Comparison With Standard PET/CT.

01-06-2016

Breast cancer research : BCR

The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening.

10-05-2016

Nederlands tijdschrift voor geneeskunde

[Ductal carcinoma in situ: the balance between over- and undertreatment].

14-04-2016

Breast cancer research and treatment

Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy.

01-04-2016

Breast cancer research and treatment

Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period.

01-04-2016

Virchows Archiv : an international journal of pathology

Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers.

01-04-2016

Clinical nuclear medicine

Additional Prone 18F-FDG PET/CT Acquisition to Improve the Visualization of the Primary Tumor and Regional Lymph Node Metastases in Stage II/III Breast Cancer.

01-04-2016

Nature

Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.

25-02-2016

Breast cancer research : BCR

Genetic predisposition to ductal carcinoma in situ of the breast.

17-02-2016

Scientific reports

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

05-01-2016

Molecular cancer therapeutics

High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer.

01-01-2016

Breast cancer research and treatment

Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups.

01-11-2015

Breast cancer research : BCR

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.

03-10-2015

European journal of cancer (Oxford, England : 1990)

Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.

01-08-2015

Breast cancer research and treatment

Fat/water ratios measured with diffuse reflectance spectroscopy to detect breast tumor boundaries.

01-08-2015

Breast cancer research and treatment

The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure.

01-08-2015

BMC medicine

Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis.

02-07-2015

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

First results of the preoperative accelerated partial breast irradiation (PAPBI) trial.

01-03-2015

Annals of surgery

Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.

01-02-2015

The journal of pathology. Clinical research

Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium.

01-01-2015

Breast cancer research and treatment

Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis.

01-12-2014

Nuclear medicine communications

Radio-guided seed localization for breast cancer excision: an ex-vivo specimen-based study to establish the accuracy of a freehand-SPECT device in predicting resection margins.

01-09-2014

International journal of cancer

PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.

01-09-2014

PloS one

Lack of genomic heterogeneity at high-resolution aCGH between primary breast cancers and their paired lymph node metastases.

02-08-2014

European journal of nuclear medicine and molecular imaging

Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy.

01-08-2014

Breast (Edinburgh, Scotland)

Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values.

01-06-2014

Breast cancer research and treatment

Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms.

01-06-2014

Nature

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

03-04-2014

PLoS genetics

Genetic predisposition to in situ and invasive lobular carcinoma of the breast.

01-04-2014

Cancer letters

Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes.

01-03-2014

The Journal of molecular diagnostics : JMD

MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue.

01-03-2014

Annals of surgical oncology

Reply to "Anti-cytokeratin CAM5.2 recognized CK8 mainly, but not CK18: comment on 'Early assessment of axillary response with 18F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla. Ann Surg Oncol. 2013;20(7):2227-35'".

01-02-2014

European journal of radiology

Avoiding preoperative breast MRI when conventional imaging is sufficient to stage patients eligible for breast conserving therapy.

01-02-2014

European journal of nuclear medicine and molecular imaging

Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy.

01-01-2014

British journal of cancer

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer.

10-12-2013

European journal of radiology

Does the pretreatment tumor sampling location correspond with metabolic activity on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy?

01-12-2013

Breast (Edinburgh, Scotland)

FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.

01-10-2013

International journal of cancer

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.

15-08-2013

Annals of surgical oncology

Guiding breast-conserving surgery in patients after neoadjuvant systemic therapy for breast cancer: a comparison of radioactive seed localization with the ROLL technique.

01-08-2013

The Journal of pathology

Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.

01-07-2013

Annals of surgical oncology

Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.

01-07-2013

Breast cancer research and treatment

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response.

01-07-2013

Breast cancer research and treatment

Platform comparisons for identification of breast cancers with a BRCA-like copy number profile.

01-06-2013

British journal of cancer

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.

28-05-2013

The breast journal

Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.

21-05-2013

Lung cancer (Amsterdam, Netherlands)

Improved identification of peripheral lung tumors by using diffuse reflectance and fluorescence spectroscopy.

01-05-2013

An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.

Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.

Prediction Model For Extensive Ductal Carcinoma In Situ Around Early-Stage Invasive Breast Cancer.

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.

Evaluation of a Hanging-Breast PET System for Primary Tumor Visualization in Patients With Stage I-III Breast Cancer: Comparison With Standard PET/CT.

The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening.

[Ductal carcinoma in situ: the balance between over- and undertreatment].

Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy.

Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period.

Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers.

Additional Prone 18F-FDG PET/CT Acquisition to Improve the Visualization of the Primary Tumor and Regional Lymph Node Metastases in Stage II/III Breast Cancer.

Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.

Genetic predisposition to ductal carcinoma in situ of the breast.

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer.

Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups.

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.

Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.

Fat/water ratios measured with diffuse reflectance spectroscopy to detect breast tumor boundaries.

The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure.

Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis.

First results of the preoperative accelerated partial breast irradiation (PAPBI) trial.

Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.

Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium.

Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis.

Radio-guided seed localization for breast cancer excision: an ex-vivo specimen-based study to establish the accuracy of a freehand-SPECT device in predicting resection margins.

PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.

Lack of genomic heterogeneity at high-resolution aCGH between primary breast cancers and their paired lymph node metastases.

Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy.

Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values.

Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms.

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

Genetic predisposition to in situ and invasive lobular carcinoma of the breast.

Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes.

MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue.

Reply to "Anti-cytokeratin CAM5.2 recognized CK8 mainly, but not CK18: comment on 'Early assessment of axillary response with 18F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla. Ann Surg Oncol. 2013;20(7):2227-35'".

Avoiding preoperative breast MRI when conventional imaging is sufficient to stage patients eligible for breast conserving therapy.

Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy.

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer.

Does the pretreatment tumor sampling location correspond with metabolic activity on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy?

FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.

Guiding breast-conserving surgery in patients after neoadjuvant systemic therapy for breast cancer: a comparison of radioactive seed localization with the ROLL technique.

Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.

Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response.

Platform comparisons for identification of breast cancers with a BRCA-like copy number profile.

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.

Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.

Improved identification of peripheral lung tumors by using diffuse reflectance and fluorescence spectroscopy.

This site uses cookies